Reset filter
Palabras clave
Nervesystemets sykdommer ×
Mostrar más Palabras clave
Tabla de contenido
  1. 1. Ensayo clínico
  2. 2. Documentación de rutina
  3. 3. Estudio de registro / cohorte
  4. 4. Seguro de calidad
  5. 5. Estándar de datos
  6. 6. Resultado reportado por el paciente
  7. 7. Especialidad médica
Modelos de datos seleccionados

Debe iniciar sesión para seleccionar modelos de datos para descargar o realizar un análisis.

18 Resultados de la búsqueda.
Relevancia Evaluación Nuevo primero Antiguo primero

Nerventra Study Study drug dispensing and return

- 8/6/16 - 1 formulario, 3 itemgroups, 22 items, 1 idioma
Itemgroups: Demographic Information, Drug dispensed, Drug dispensing and return
Nerventra Study (Eudra CT 2007-003226-19) Study MS-LAQ-301: A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the safety, tolerability and efficacy of daily oral administration of laquinimod 0.6 mg in subjects with relapsing remitting multiple sclerosis (RRMS)

Nerventra Study Screening - Nerventra Study Sreening

- 6/6/16 - 1 formulario, 13 itemgroups, 192 items, 1 idioma
Itemgroups: Informed Consent and Demography Data, Multiple sclerosis history, Medical history, Safety measurements, Physical examination, FS,Ambulation,EDSS,AI, Timed 25-foot walk, Inclusion criteria, Exclusion criteria, Ancillary studies, Pharmacogenetic information, Subject disposition, Comments
Nerventra Study (Eudra CT 2007-003226-19) Study MS-LAQ-301: A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the safety, tolerability and efficacy of daily oral administration of laquinimod 0.6 mg in subjects with relapsing remitting multiple sclerosis (RRMS)

Nerventra Study Unscheduled Visit

- 8/6/16 - 1 formulario, 4 itemgroups, 38 items, 1 idioma
Itemgroups: Demographic Information, Reason for unscheduled visit, Safety measurements, Exacerbation
Nerventra Study (Eudra CT 2007-003226-19) Study MS-LAQ-301: A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the safety, tolerability and efficacy of daily oral administration of laquinimod 0.6 mg in subjects with relapsing remitting multiple sclerosis (RRMS)

Nerventra Study Laboratory data

- 8/6/16 - 1 formulario, 2 itemgroups, 12 items, 1 idioma
Itemgroups: Demographic Information, Laboratory parameter
Nerventra Study (Eudra CT 2007-003226-19) Study MS-LAQ-301: A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the safety, tolerability and efficacy of daily oral administration of laquinimod 0.6 mg in subjects with relapsing remitting multiple sclerosis (RRMS)

Nerventra Study Medication log

- 8/6/16 - 1 formulario, 3 itemgroups, 19 items, 1 idioma
Itemgroups: Demographic Information, Medication log, Concomitant medications log
Nerventra Study (Eudra CT 2007-003226-19) Study MS-LAQ-301: A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the safety, tolerability and efficacy of daily oral administration of laquinimod 0.6 mg in subjects with relapsing remitting multiple sclerosis (RRMS)

Nerventra Study Visit 8

- 8/6/16 - 1 formulario, 2 itemgroups, 11 items, 1 idioma
Itemgroups: Informed Consent and Demography Data, Pasat Summary Score Sheet
Nerventra Study (Eudra CT 2007-003226-19) Study MS-LAQ-301: A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the safety, tolerability and efficacy of daily oral administration of laquinimod 0.6 mg in subjects with relapsing remitting multiple sclerosis (RRMS)

Nerventra Study Visit 10

- 8/6/16 - 1 formulario, 2 itemgroups, 25 items, 1 idioma
Itemgroups: Demographic Information, Safety measurements
Nerventra Study (Eudra CT 2007-003226-19) Study MS-LAQ-301: A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the safety, tolerability and efficacy of daily oral administration of laquinimod 0.6 mg in subjects with relapsing remitting multiple sclerosis (RRMS)

Nerventra Study Visit 4

- 8/6/16 - 1 formulario, 2 itemgroups, 19 items, 1 idioma
Itemgroups: Demographic Information, 9-Hole Peg test
Nerventra Study (Eudra CT 2007-003226-19) Study MS-LAQ-301: A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the safety, tolerability and efficacy of daily oral administration of laquinimod 0.6 mg in subjects with relapsing remitting multiple sclerosis (RRMS)

Nerventra Study Liver enzyme evaluation

- 8/6/16 - 1 formulario, 2 itemgroups, 34 items, 1 idioma
Itemgroups: Demographic Information, Evaluation of liver enzymes
Nerventra Study (Eudra CT 2007-003226-19) Study MS-LAQ-301: A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the safety, tolerability and efficacy of daily oral administration of laquinimod 0.6 mg in subjects with relapsing remitting multiple sclerosis (RRMS)

Nerventra Study Adverse event log

- 8/6/16 - 1 formulario, 4 itemgroups, 38 items, 1 idioma
Itemgroups: Demographic Information, Ongoing adverse events, Adverse events log Baseline, Adverse events Visit 1
Nerventra Study (Eudra CT 2007-003226-19) Study MS-LAQ-301: A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the safety, tolerability and efficacy of daily oral administration of laquinimod 0.6 mg in subjects with relapsing remitting multiple sclerosis (RRMS)

Nerventra Study Sustained increase in EDSS

- 8/6/16 - 1 formulario, 2 itemgroups, 10 items, 1 idioma
Itemgroups: Demographic Information, Sustained increase in EDSS
Nerventra Study (Eudra CT 2007-003226-19) Study MS-LAQ-301: A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the safety, tolerability and efficacy of daily oral administration of laquinimod 0.6 mg in subjects with relapsing remitting multiple sclerosis (RRMS)

Nerventra Study Termination/Early termination

- 8/6/16 - 1 formulario, 2 itemgroups, 12 items, 1 idioma
Itemgroups: Demographic Information, Termination/Early termination
Nerventra Study (Eudra CT 2007-003226-19) Study MS-LAQ-301: A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the safety, tolerability and efficacy of daily oral administration of laquinimod 0.6 mg in subjects with relapsing remitting multiple sclerosis (RRMS)

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial